Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD:
DEADLINE:
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
DJS Law Group
Phone: 914-206-9742
Email: [email protected]
View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302714246.html
SOURCE DJS Law Group LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beyond the Credential: As AI Erases the 'Entry-Level Job' and Climate Volatility Accelerates, Planet Classroom Unveils July Lineup Mapping the New Rules of Human Resilience
- Strategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics
- Crypto News: AlphaPepe Reveals CEX Partnership With Biconomy As Ethereum Price Prediction Targets $7,000
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share